| Bioactivity | PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy[1]. |
| Invitro | PPAR agonist 4 (3-10 μM) 剂量依赖性地上调 HepG2 细胞中 PPARα/δ 靶基因 CPT1A，PDK4 和 ANGPTL4 以及 HEK293 细胞中 PPARγ 靶基因 CD36 和 FABP4 的表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PPAR agonist 4 相关抗体: RT-PCR[1] Cell Line: |
| In Vivo | PPAR agonist 4 (3-30 mg/kg，口服，3 周) 可改善 CCl4 诱导的肝纤维化小鼠模型中的胶原沉积并抑制炎症细胞浸润[1]。PPAR agonist 4 在SD 大鼠体内的药代动力学分析[1]route |
| Formula | C23H28F3N3O3 |
| Molar Mass | 451.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sun G, et al., Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis. Eur J Med Chem. 2024 Apr 5;269:116344. |